ArriVent BioPharma Files 2024 10-K
Ticker: AVBP · Form: 10-K · Filed: Mar 3, 2025 · CIK: 1868279
| Field | Detail |
|---|---|
| Company | Arrivent Biopharma, INC. (AVBP) |
| Form Type | 10-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, biopharma
TL;DR
ArriVent BioPharma filed its 2024 10-K. Check financials.
AI Summary
ArriVent BioPharma, Inc. filed its 2024 10-K on March 3, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, incorporated in Delaware, operates in the pharmaceutical preparations sector. Key financial details and operational highlights for the period are detailed within the filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of ArriVent BioPharma's financial health, strategic direction, and risks for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, ArriVent BioPharma is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 238333000 — Total Assets (Reported for the fiscal year ending 12-31-2024)
Key Players & Entities
- ArriVent BioPharma, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-03 (date) — Filing date
- 18 CAMPUS BLVD., SUITE 100, NEWTOWN SQUARE, PA 19073-3269 (address) — Company business and mailing address
- 240-780-6356 (phone_number) — Company business phone
FAQ
What were ArriVent BioPharma's total revenues for the fiscal year ending December 31, 2024?
The provided text does not explicitly state the total revenues for the fiscal year ending December 31, 2024. It focuses on asset information and other financial statement line items.
What is the company's primary business activity?
ArriVent BioPharma, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
When did ArriVent BioPharma change its name from ArriVent Biopharma, Inc.?
The company formerly known as ArriVent Biopharma, Inc. changed its name on June 17, 2021.
What is the company's SEC file number?
The SEC file number for ArriVent BioPharma, Inc. is 001-41929.
What significant events occurred on January 30, 2024, according to the filing?
On January 30, 2024, there were events related to ArriVent BioPharma's common stock, including the exercise of an over-allotment option and an Initial Public Offering (IPO).
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 3, 2025 regarding ArriVent BioPharma, Inc. (AVBP).